1. Anticancer mechanism studies of iridium(III) complexes inhibiting osteosarcoma HOS cells proliferation.
- Author
-
Xie FL, Wang Y, Zhu JW, Xu HH, Guo QF, Wu Y, and Liu SH
- Subjects
- Humans, Iridium pharmacology, Reactive Oxygen Species metabolism, Phenanthrolines pharmacology, Phosphatidylinositol 3-Kinases, Cell Line, Tumor, Cell Proliferation, Apoptosis, Coordination Complexes pharmacology, Antineoplastic Agents pharmacology, Osteosarcoma drug therapy
- Abstract
Three iridium (III) polypyridine complexes [Ir(bzq)
2 (maip)](PF6 ) (Ir1,bzq = benzo[h]quinoline, maip = 3-aminophenyl-1H-imidazo[4,5-f][1,10]phenanthroline), [Ir(bzq)2 (apip)](PF6 ) (Ir2, apip = 2-aminophenyl-1H-imidazo[4,5-f][1,10]phenanthroline) and [Ir(bzq)2 (paip)](PF6 ) (Ir3, paip = 4-aminophenyl-1H-imidazo[4,5-f][1,10]phenanthroline) were synthesized and characterized. The cytotoxic activities of the three complexes against human osteosarcoma HOS, U2OS, MG63 and normal LO2 cells were evaluated by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) method. The results showed that Ir1-3 exhibited moderate antitumor activity against HOS with IC50 of 21.8 ± 0. 4 μM,10.5 ± 1.8 μM and 7.4 ± 0.4 μM, respectively. We found that Ir1-3 can effectively inhibit HOS cells growth and blocked the cell cycle at the G0/G1 phase. Further studies revealed that complexes can increase intracellular reactive oxygen species (ROS) and Ca2+ , which accompanied by mitochondria-mediated intrinsic apoptosis pathway. In addition, autophagy was also investigated. Taken together, the complexes induce HOS apoptosis through a ROS-mediated mitochondrial dysfunction pathway and inhibition of the PI3K (phosphatidylinositol 3-kinase)/AKT (protein kinase B)/mTOR (mammalian target of rapamycin) signaling pathway. This study provides useful help for understanding the anticancer mechanism of iridium (III) complexes toward osteosarcoma treatment., Competing Interests: Declaration of Competing Interest The authors have declared that no competing interest exists., (Copyright © 2022 Elsevier Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF